BioTime Stock Price, News & Analysis (NYSEAMERICAN:BTX)

$2.43 0.00 (0.00 %)
(As of 12/11/2017 02:43 AM ET)
Previous Close$2.43
Today's Range$2.40 - $2.46
52-Week Range$2.19 - $3.97
Volume303,800 shs
Average Volume352,676 shs
Market Capitalization$308.28 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03

About BioTime (NYSEAMERICAN:BTX)

BioTime logoBioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNYSEAMERICAN:BTX
CUSIP09066L10
Phone+1-510-5213390

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$0.43
Net IncomeN/A
Net Margins828.55%
Return on Equity30.68%
Return on Assets27.02%

Miscellaneous

EmployeesN/A
Outstanding Shares126,870,000

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) issued its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.06. The biotechnology company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.75 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%. View BioTime's Earnings History.

Where is BioTime's stock going? Where will BioTime's stock price be in 2017?

2 brokerages have issued 12 month target prices for BioTime's shares. Their forecasts range from $6.00 to $6.50. On average, they anticipate BioTime's share price to reach $6.25 in the next year. View Analyst Ratings for BioTime.

Are investors shorting BioTime?

BioTime saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 6,852,827 shares, an increase of 1.3% from the October 31st total of 6,767,992 shares. Based on an average daily volume of 401,932 shares, the short-interest ratio is currently 17.0 days. Approximately 5.8% of the shares of the company are short sold.

Who are some of BioTime's key competitors?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:

  • Alfred D. Kingsley, Chairman of the Board (Age 74)
  • Aditya P. Mohanty, Co-Chief Executive Officer, Director (Age 50)
  • Michael D. West Ph.D., Co-Chief Executive Officer, Director (Age 63)
  • Russell L. Skibsted, Chief Financial Officer (Age 58)
  • Judith Segall, Vice President, Secretary (Age 61)
  • Stephana Eilene Patton Ph.D., J.D., General Counsel (Age 46)
  • Deborah J. Andrews, Independent Director (Age 59)
  • Neal C. Bradsher, Independent Director (Age 51)
  • Stephen C. Farrell CPA, Independent Director (Age 52)
  • Michael H. Mulroy, Independent Director (Age 51)

Who owns BioTime stock?

BioTime's stock is owned by a number of of institutional and retail investors. Top institutional investors include Broadwood Capital Inc. (22.64%), IndexIQ Advisors LLC (0.22%), Family Management Corp (0.15%), GSA Capital Partners LLP (0.14%), Dimensional Fund Advisors LP (0.13%) and Schwab Charles Investment Management Inc. (0.09%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.

Who sold BioTime stock? Who is selling BioTime stock?

BioTime's stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc. and Russell Investments Group Ltd.. View Insider Buying and Selling for BioTime.

Who bought BioTime stock? Who is buying BioTime stock?

BioTime's stock was acquired by a variety of institutional investors in the last quarter, including Broadwood Capital Inc., IndexIQ Advisors LLC, GSA Capital Partners LLP, Family Management Corp, Dimensional Fund Advisors LP and Jane Street Group LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.

How do I buy BioTime stock?

Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BioTime stock can currently be purchased for approximately $2.43.

How big of a company is BioTime?

BioTime has a market capitalization of $308.28 million.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.


MarketBeat Community Rating for BioTime (BTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioTime (NYSEAMERICAN:BTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.25$6.25$6.25$6.75
Price Target Upside: 106.27% upside106.27% upside106.27% upside103.93% upside

BioTime (NYSEAMERICAN:BTX) Consensus Price Target History

Price Target History for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN:BTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
6/19/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$6.00 -> $6.50View Rating Details
3/31/2017Raymond James FinancialInitiated CoverageOutperform -> Outperform$6.00View Rating Details
4/7/2016Chardan CapitalInitiated CoverageBuyView Rating Details
4/2/2016OppenheimerReiterated RatingBuyView Rating Details
(Data available from 12/11/2015 forward)

Earnings

BioTime (NYSEAMERICAN:BTX) Earnings History and Estimates Chart

Earnings by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016Q316($0.14)($0.08)$1.46 million$1.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.17)($0.11)$1.75 million$1.27 millionViewN/AView Earnings Details
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
3/15/2016Q4($0.17)($0.16)$1.31 millionViewN/AView Earnings Details
8/10/2015Q2($0.12)$2.01 millionViewN/AView Earnings Details
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)$0.61 million$1.07 millionViewN/AView Earnings Details
11/12/2013Q3($0.16)ViewN/AView Earnings Details
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

BioTime (NYSEAMERICAN:BTX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for BioTime (NYSEAMERICAN:BTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioTime (NYSEAMERICAN BTX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for BioTime (NYSEAMERICAN:BTX)
Insider Trades by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2017Broadwood Partners, L.P.DirectorBuy2,692,307$2.60$6,999,998.20View SEC Filing  
8/23/2017Russell SkibstedCFOBuy2,000$2.64$5,280.00View SEC Filing  
8/22/2017Broadwood Partners, L.P.DirectorBuy10,000$2.60$26,000.00View SEC Filing  
8/22/2017Michael D. WestCEOBuy2,000$2.60$5,200.00View SEC Filing  
8/21/2017Aditya P. MohantyCEOBuy7,500$2.50$18,750.00View SEC Filing  
8/21/2017Deborah J AndrewsDirectorBuy2,396$2.50$5,990.00View SEC Filing  
7/31/2017Broadwood Partners, L.P.DirectorBuy150,000$2.80$420,000.00View SEC Filing  
6/16/2017Deborah J AndrewsDirectorBuy2,000$2.95$5,900.00View SEC Filing  
5/16/2017Deborah J AndrewsDirectorBuy2,000$3.21$6,420.00View SEC Filing  
2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.00View SEC Filing  
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.00View SEC Filing  
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.00View SEC Filing  
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioTime (NYSEAMERICAN BTX) News Headlines

Source:
DateHeadline
ETFs with exposure to BioTime, Inc. : December 7, 2017ETFs with exposure to BioTime, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:36 PM
BioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in EuripeBioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in Euripe
www.streetinsider.com - December 5 at 10:21 AM
BioTime, Inc. :BTX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017BioTime, Inc. :BTX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 10:21 AM
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and StratasysZacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
finance.yahoo.com - December 5 at 10:21 AM
BioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in Euripe - StreetInsider.comBioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in Euripe - StreetInsider.com
www.streetinsider.com - December 4 at 5:11 PM
AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering ...AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering ...
www.businesswire.com - December 4 at 9:36 AM
AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, NCAgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, NC
finance.yahoo.com - December 4 at 9:36 AM
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTimeZacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
finance.yahoo.com - December 1 at 5:00 PM
Data from BioTime’s Renevia ® Program to Be Presented at IFATS ConferenceData from BioTime’s Renevia ® Program to Be Presented at IFATS Conference
www.businesswire.com - November 30 at 10:08 AM
Data from BioTime’s Renevia® Program to Be Presented at IFATS ConferenceData from BioTime’s Renevia® Program to Be Presented at IFATS Conference
finance.yahoo.com - November 30 at 10:08 AM
5 Affordable Breakout Stocks Offering Excellent Returns5 Affordable Breakout Stocks Offering Excellent Returns
finance.yahoo.com - November 30 at 10:08 AM
BioTime, Inc. is trading above its 50 day moving average : BTX-US : November 29, 2017BioTime, Inc. is trading above its 50 day moving average : BTX-US : November 29, 2017
finance.yahoo.com - November 29 at 9:45 AM
BioTime, Inc. – Value Analysis (NYSE AMERICAN:BTX) : November 28, 2017BioTime, Inc. – Value Analysis (NYSE AMERICAN:BTX) : November 28, 2017
finance.yahoo.com - November 28 at 5:12 PM
BioTime, Inc. (BTX) Short Interest Up 1.3% in NovemberBioTime, Inc. (BTX) Short Interest Up 1.3% in November
www.americanbankingnews.com - November 27 at 7:48 PM
BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : November 27, 2017BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : November 27, 2017
finance.yahoo.com - November 27 at 6:26 PM
BioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data - StreetInsider.comBioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data - StreetInsider.com
www.streetinsider.com - November 16 at 10:13 PM
BioTime, Inc.: Trading close to its 50 day moving average. Good buy?BioTime, Inc.: Trading close to its 50 day moving average. Good buy?
finance.yahoo.com - November 16 at 12:14 PM
BioTime, Inc. (BTX) Lifted to Buy at Zacks Investment ResearchBioTime, Inc. (BTX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM

SEC Filings

BioTime (NYSEAMERICAN:BTX) SEC Filings

DateFilerForm TypeView

Social Media

Financials

BioTime (NYSEAMERICAN:BTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioTime (NYSEAMERICAN BTX) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.